ALEXANDRIA, Va., April 21 -- United States Patent no. 12,605,451, issued on April 21, was assigned to Novartis AG (Basel, Switzerland).
"Targeted plasma protein degradation" was invented by Martin Allan (Worcester, Mass.), Jeffrey T. Bagdanoff (Quincy, Mass.), David Weninger Barnes (Waban, Mass.), Kevin Clairmont (Acton, Mass.), Thomas Smith (Arlington, Mass.) and Shuangxi Wang (Auburndale, Mass.).
According to the abstract* released by the U.S. Patent & Trademark Office: "The present invention is directed to the bifunctional compounds and the use of such bifunctional compounds to lower plasma levels of extracellular target molecules by lysosomal degradation. Such bifunctional compounds have a cell surface receptor ligand covalently linke...